European regulators moved to pull Amgen’s Tavneos from the market, citing that evidence submitted for the original approval could no longer be relied upon. The EMA committee recommended withdrawal after finding the data package “incorrect and misleading,” undermining the basis for demonstrating effectiveness. The decision follows a similar line from the FDA, where a withdrawal proposal is also moving through the process, with CHMP support reinforcing the integrity concerns. The Tavneos case is now centered on whether regulators can trust the Advocate study data that supported the original application and whether remediation is possible. For biotech strategy, the Tavneos revocation signals that even already-approved rare-disease therapies can face abrupt reversals when data integrity questions escalate at the agency level. It also raises the bar for sponsors to ensure trial documentation withstands cross-agency scrutiny long after initial marketing authorization.